Ratings SNDL Inc.

Equities

SNDL

CA83307B1013

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
2.01 ^USD	0.00%		+6.91%	+22.56%

02/04	Cannabis Stocks Rise Pre-Bell After Florida Supreme Court Allows Ballot Initiative to Legalize Marijuana	MT
02/04	Pot producers climb as recreational cannabis to go on Florida ballot	RE

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SNDL INC.	+22.56%	529M	D+
ELI LILLY AND COMPANY	+26.47%	664B	C+
NOVO NORDISK A/S	+26.74%	567B	B
JOHNSON & JOHNSON	-6.33%	354B	C+
MERCK & CO., INC.	+19.35%	330B	B-
ABBVIE INC.	+4.23%	286B	C+
ASTRAZENECA PLC	+13.43%	234B	B+
NOVARTIS AG	+4.71%	199B	B-
ROCHE HOLDING AG	-9.53%	196B	A+
AMGEN INC.	-4.04%	148B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes